Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects
出版年份 2023 全文链接
标题
Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects
作者
关键词
-
出版物
CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-11-04
DOI
10.1002/cncr.35093
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers
- (2023) Limin Zou et al. Cancer Communications
- Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
- (2023) Chenchen Ji et al. ONCOLOGIST
- Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
- (2023) G. Antonarelli et al. ESMO Open
- Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
- (2023) Andrea D’Arienzo et al. EClinicalMedicine
- Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
- (2022) Giampaolo Bianchini et al. Cancers
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The therapeutic window of antibody drug conjugates: A dogma in need of revision
- (2022) Raffaele Colombo et al. CANCER CELL
- CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition
- (2022) Xinwei Liu et al. CANCER CELL
- The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
- (2022) Claudia von Arx et al. CANCER TREATMENT REVIEWS
- Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
- (2022) Yu‐Fei Chen et al. Cancer Communications
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
- (2021) Paolo Tarantino et al. JAMA Oncology
- ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer
- (2020) Mark Barok et al. CANCER LETTERS
- Acquired Resistance to Antibody-Drug Conjugates
- (2019) Denis Collins et al. Cancers
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
- (2017) Ricarda M. Hoffmann et al. OncoImmunology
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ado-trastuzumab Emtansine
- (2014) Patricia A. Corrigan et al. ANNALS OF PHARMACOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started